
Fortis Healthcare Q1 Results FY26: Q1 PAT Rises 56.83% to ₹260.28 Crore; Revenue Up 16.56% YoY
Q1 Results FY26
Updated: 7 Aug 2025 • 11:59 am
Posted by:

Fortis Healthcare Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)
| Particulars | Quarter Ended | |
| 30-06-2025 | 30-06-2024 | |
| Revenue from Operations | ₹2,166.72 | ₹1,858.90 |
| Profit Before Tax (PBT) | ₹506.07 | ₹355.53 |
| Profit After Tax (PAT) | ₹260.28 | ₹165.96 |
(Figures in crores)
Fortis Healthcare Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)
| Particulars | Quarter Ended | |
| 30-06-2025 | 30-06-2024 | |
| Revenue from Operations | ₹433.03 | ₹333.40 |
| Profit Before Tax (PBT) | ₹128.12 | ₹93.37 |
| Profit After Tax (PAT) | ₹51.88 | ₹26.83 |
(Figures in crores)
Fortis Healthcare Q1 Results FY26 Highlights (Q1 FY26 vs FY25)
- Fortis Healthcare clocked Q1 FY26 consolidated revenue of ₹2,166.72 crores vs ₹1,858.90 crores.
- On the profit front, Fortis Healthcare earned a consolidated PAT of ₹260.28 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹165.96 crore.
- Consolidated PAT rose for the first quarter of FY26, was 56.83% YoY, and revenue rose 16.56% YoY.
- As per the standalone figures, the quarterly PAT of Fortis Healthcare has increased by 93.37%, and revenue has increased by 29.88% YoY.
Fortis Healthcare Share Price Performance
On the opening bell of 7th August 2025, the shares of Fortis Healthcare opened at ₹881.95 per share. However, the initial gains are sustained as of now, and Fortis Healthcare shares are trading at ₹887.90 per share, higher than their opening price.
Considering the long-term performance, Fortis Healthcare shares have yielded close to 82.70% returns in the past 1 year, and 5-year returns stand at 543.48%. Over the maximum timeframe, the Fortis Healthcare share provided 783.58% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Fortis Healthcare shares after thorough research.
For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Also Read : Maruti Suzuki Q1 Results FY26: Q1 PAT Soars 0.87% to ₹3,792.40 Crore; Revenue Surged 7.90% YoY
Recent Articles
RITES Q1 Results FY26: Q1 PAT Jumps 1.37% to ₹80.10 Crore; Revenue Surges 0.82% YoY
Godrej Agrovet Q1 Results FY26: Q1 Rises 18.77% to ₹160.52 Crore; Revenue Soars 11.21% YoY
Recent Articles

Jindal Poly Films Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
16 June 2026

Kalyan Jewellers Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
16 June 2026

Avadh Sugar Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
16 June 2026

Avanti Feeds Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
16 June 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Jindal Poly Films Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Kalyan Jewellers Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Avadh Sugar Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Avanti Feeds Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Venky India Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Popular this week
Jindal Poly Films Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Kalyan Jewellers Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Avadh Sugar Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Avanti Feeds Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Venky India Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas





